NOTICE
TO READERS: The
press releases, presentations, printed remarks,
footage and publications that are included
on our website are for historical purposes
only. The information contained in these materials
should be considered accurate only as of the
date of the relevant item. This information
may change over time, and visitors to this
website should not assume that the information
contained in these materials remains accurate
at a later time. Oculus Innovative Sciences,
Inc. disclaims any intention to supplement,
update or revise any of the information contained
in these materials.
Archived Press Releases
....................................................................................................................................................................................
These press releases about Oculus Incorporated
are sorted by date, with the most recent at the
top. You will need the free Adobe®
Reader® to view the PDFs.
2008
March 28,
2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million
Securities Offering
March 27,
2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory
Approval of Microcyn® Technology
March 17,
2008
Oculus
Innovative Sciences Announces Positive Results
From Three Abstracts Evaluating the Use of
Microcyn®
Technology in Diabetic Foot Ulcers
March 14,
2008
Oculus
Innovative Sciences Announces Additional Phase
II Data for Microcyn® Technology in Mildly
Infected Diabetic Foot Ulcers
March 12,
2008
Oculus
Innovative Sciences Announces Acceptance of
Three Abstracts on the use of Microcyn® Technology
in Diabetic Foot Ulcers by DFCon 08
March 11,
2008
Oculus
Innovative Sciences to Announce Additional
Phase II Data and Data from Two Recent International
Studies at DFCon 08
February
27, 2008
Oculus
Innovative Sciences Schedules Conference Call
Today to Discuss Positive Top-Line Phase II
Data with Microcyn® Technology in Mildly
Infected Diabetic Foot Ulcers
February
27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line
Phase II Data with Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
February
14, 2008
Oculus
Innovative Sciences to Present at the Roth
Capital Partners 20th Annual OC Growth Stock
Conference
February
7, 2008
Oculus
Innovative Sciences Announces Fiscal Third
Quarter 2008 Quarterly Results and Clinical
Update
February
5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial
Results Release and Conference Call
January
29, 2008
Oculus
Innovative Sciences Announces Agreement with
Animal Health International for North American
Distribution of Microcyn®-Based Vetericyn™ Wound
Spray
January
24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal
Court in Intellectual Property Rights Litigation
January
22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase
II Trial to Be Presented at DFCon 08 (Diabetic
Foot Global Conference) on March 14, 2008
January
17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg
Alton to its Board of Directors
January
3, 2008
Oculus
Innovative Sciences Completes Patient Treatment
and Follow-up in Its Phase II Clinical Trial
in Mildly Infected Diabetic Foot Ulcers
2007
December 18,
2007
Oculus
Innovative Sciences Announces Completion of
Two Randomized Controlled Clinical Trials of
Microcyn® Technology in China
December 5,
2007
Oculus
Innovative Sciences Completes Enrollment of
Phase II Trial of Microcyn® Technology
in Treatment of Mildly Infected Diabetic Foot
Ulcers
November 19,
2007
Oculus
Innovative Sciences Wins Federal Court Ruling
in Intellectual Property Rights Litigation
November 12,
2007
Oculus
Innovative Sciences Announces Fiscal Second
Quarter 2008 Quarterly Results and Clinical
Update
November 8,
2007
Oculus
Innovative Sciences Schedules Fiscal Second
Quarter 2008 Financial Results Release and
Conference Call
November 1,
2007
Oculus
Innovative Sciences to Present at SMH Capital
Markets Investor Growth Conference
October 30,
2007
Oculus
Innovative Sciences to Present at Acumen
BioFin 9th Annual Healthcare Conference
October 3,
2007
Oculus
Innovative Sciences to Present at 4th Annual
BIO InvestorForum Conference
September
17, 2007
Oculus
Innovative Sciences Microcyn Technology Data
to be Presented by Researchers at the 47th
Interscience Conference on Antimicrobial
Agents and Chemotherapy
September
17, 2007
Oculus
Innovative Sciences Provides Update of Phase
II Study for Microcyn® Technology in
Mildly Infected Diabetic Foot Ulcers
September
14, 2007
Oculus
Innovative Sciences to Conduct Conference
Call Update on Phase II Study of Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September
6, 2007
Oculus
Innovative Sciences to Present at First Albany
Capital Regenerative Technologies Conference
August 29,
2007
Oculus
Innovative Sciences to Present at Roth Capital
Partners 2007 New York Conference
August 9,
2007
Oculus
Innovative Sciences Announces Fiscal First
Quarter 2008 Financial Results
August 8,
2007
Oculus
Innovative Sciences Announces $10.1 Million
Private Placement of Common Stock
August 3,
2007
Oculus
Innovative Sciences Schedules Fiscal First
Quarter 2008 Financial Results Release and
Conference Call
June 26, 2007
Oculus
Innovative Sciences Announces Results From
Anti-Inflammatory Study Using Microcyn® Technology
June 18, 2007
Oculus
Innovative Sciences Appoints Vice President
of Regulatory Affairs and Quality
June 13, 2007
Drug
Enhancement Company of America Licenses Oculus'
Microcyn®
Technology for Use in First Responder ''Pen-Like''
Applicator
June 7, 2007
Oculus
Announces Fiscal Fourth Quarter and Full
Year 2007 Financial Results
June 6, 2007
Oculus
Schedules Fiscal Fourth Quarter and Full Year 2007
Financial Results Release and Conference Call
May 21, 2007
Oculus
Initiates Patient Enrollment in Phase II Study
of Microcyn®
Technology for Treatment of Mild Diabetic
Foot Infections
May 14, 2007
Oculus
Innovative Sciences Microcyn® Technology
Presented in Poster at European Wound Management
Association Conference
May 9, 2007
Oculus
Innovative Sciences to Present at Rodman & Renshaw
Global Healthcare Conference
April 26,
2007
China
Bao Tai, Sinopharm and Lianhua Supermarkets
to Distribute Oculus' Microcyn®-Based Wound
Care Solution in China
April 25,
2007
Oculus
Innovative Sciences, Inc. Appoints Jay E. Birnbaum
to Its Board of Directors
March 29,
2007
Oculus
Announces Initial Sites for Phase II Clinical
Trial of Microcyn® Technology in Treatment
of Mild Diabetic Foot Infections
February 22,
2007
Oculus
Innovative Sciences Announces Fiscal Third
Quarter 2007 Results
January 24,
2007
Oculus
Innovative Sciences, Inc. Announces Initial
Public Offering
2006
July 11, 2006
Pharmaceutical
Veteran Michael Wokasch Joins Oculus Innovative
Sciences As Chief Operating Officer
March 8, 2006
Dermacyn® Wound
Care OTC receives FDA clearance for over-the-counter
sales
in the United States.
2005
October 4,
2005
Results
of Clinical Study Evaluating Treatment of Diabetic
Foot Ulcers Using Microcyn® Technology
Presented At Stuttgart2005.
June 17, 2005
Oculus
Innovative Sciences Announces Company's First
U.S. Clinical Trial On Humans.
May 18, 2005
Oculus
Innovative Sciences Announces Second FDA 510k
Clearance of Microcyn® Technology.
May 9, 2005
Oculus
Innovative Sciences Announces FDA 510k Clearance
of Microcyn®
Technology.
2004
November 24, 2004
Dermacyn®
Wound Care From Oculus Innovative Sciences
Receives CE Mark Approval For Treating Acute
and Chronic Wounds In Europe.
(PDF: 82 KB)
November 19, 2004
European
Facility is Approved for Manufacturing of Revolutionary
Microcyn® Technology.
(PDF: 88 KB)
November 1,
2004
Oculus
Receives Regulatory Approval To Market Dermacyn®
Wound Care in Canada.
May 14, 2004
Oculus
Files 510(K) with FDA for Approval of Microcyn
as Wound Care Dressing.
(PDF: 92 KB)
May 14, 2004
Oculus
Files Application with U.S. EPA for Approval
of Microcyn as a Hospital-Grade Disinfectant.
(PDF: 90 KB)
May 1, 2004
Oculus
Closes Series "A" Round of Financing
for $8 Million.
(PDF: 93 KB)
April 16,
2004
Mexican
Ministry of Health Approves Microcyn Technology
for Use in Veterinarian Market.
(PDF: 93 KB)
March 31,
2004
Oculus
Microcyn60 Disinfectant (OMD) Technology Receives
CE Mark Approval as Disinfectant for Non-Critical
Medical Devices in Europe.
(PDF: 94 KB)
January 9,
2004
Oculus
Applies for CE Mark Approval for California
Manufacturing Facility. (Corrected Jan. 11,
2004)
(PDF: 92 KB)
January 9,
2004
Microcyn
Receives Approval as a Sterilant from Mexican
Ministry of Health.
(PDF: 90 KB)
2003
December 19,
2003
Oculus
Completes Incorporation of Legal Entity in
the Netherlands and Prepares for Opening of
European Manufacturing Facility for Microcyn
Technology.
(PDF: 92 KB)
November 11,
2003
Oculus
Innovative Sciences Launches Microcyn in Mexico.
(PDF: 94 KB)
October 1,
2003
Oculus
Files for Pre-Investigational Meeting with
FDA to Review Microcyn60 Antiseptic Technology.
(PDF: 90 KB)
September
18, 2003
MicroMed
Consulting Group Announces Strategic Partnership
with Roberts Consulting & Engineering.
(PDF: 92 KB)
September
9, 2003
Oculus
Innovative Sciences Opens European Office as
Company Seeks CE Mark Approval of Microcyn60
Disinfectant and Antiseptic.
(PDF: 91 KB)
September
9, 2003
Jim
Schutz Joins Oculus Innovative Sciences as
General Counsel and Corporate Secretary.
(PDF: 90 KB)
September
2, 2003
Dr.
Andres Gutierrez of Mexican Ministry of Health
Joins Oculus Advisory Board.
(PDF: 91 KB)
August 28,
2003
Mexico's
Ministry of Health to Initiate Limited Clinical
Trials of Oculus's "L3" Oncology
Compound in Treatment of Cervical Cancer.
(PDF: 92 KB)
August 14,
2003
Oculus
Innovative Sciences Announces Appointment of
Executive Vice President and Director of Business
Development.
(PDF: 93 KB)
July 31, 2003
Microcyn60
Disinfectant from Oculus Innovative Sciences
Receives Mexican Ministry of Health Approval.
(PDF: 92 KB) |
